Studies currently underway
The combined overall survival analysis of the three first-line studies, SIRFLOX, FOXFIRE and FOXFIRE Global are planned for 2017 will hopefully give clinicians guidance as to the role of SIRT in chemo-naive patients and the current guidelines will be updated when this information is available::
- SIRFLOX (NCT00724503): a randomised multicentre trial comparing SIRFLOX - FOLFOXSystemic chemotherapy using a combination of the drugs Leucovorin (folinic acid), Fluorouracil, and Oxaliplatin. plus SIR-SPHERES MICROSPHERES vs. FOLFOXSystemic chemotherapy using a combination of the drugs Leucovorin (folinic acid), Fluorouracil, and Oxaliplatin. alone in patients with liver metastases from primary colorectal cancer.
- FOXFIRE (ISRCTN83867919): an open-label randomised phase III trial of 5-Fluorouracil, Oxaliplatin and Folinic acid +/- Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer.
- FOXFIRE Global (NCT01721954): a randomised multicentre trial comparing FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in patients with liver metastases from primary colorectal cancer.
It has been hypothesized that pulmonary metastases may behave in a more indolent fashion and control of hepatic metastases will therefore improve survival, however, this question will not be answered until the overall survival results are presented (in combination with FOXFIRE and FOXFIRE Global studies).